LENZ实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (21 May 2024 @ 21:44):

LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia...

Stats
今日成交量	3 955.00
平均成交量	287 672
市值	477.48M
EPS	$0 ( 2024-05-09 )
下一个收益日期	( $-0.420 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0450 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-14	Chevallard Daniel R.	Buy	3 188	Common Stock
2024-05-13	Mccollum James W	Buy	31 332	Common Stock
2024-03-21	Alpha Wave Ventures Gp, Ltd	Buy	0	Common Stock, par value $0.00001 per share
2024-03-21	Ra Capital Management, L.p.	Buy	933 038	Common Stock
2024-03-21	Ra Capital Management, L.p.	Buy	2 386 301	Common Stock

INSIDER POWER
98.20
Last 38 transactions
Buy: 7 772 479 \| Sell: 70 534

音量相关性

長: 0.17 (neutral)

短: -0.24 (neutral)

Signal:(55.305) Neutral

LENZ Therapeutics, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

LENZ Therapeutics, Inc. 相关性 - 货币/商品

-0.45
( neutral )

0.50
( neutral )

0.00
( neutral )

-0.72
( moderate negative )

0.67
( moderate )

0.11
( neutral )

LENZ Therapeutics, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-2.41M (0.00 %)
EPS:	$-15.30

FY	2023
营收:	$0
毛利润:	$-2.41M (0.00 %)
EPS:	$-15.30

Financial Reports:

No articles found.

LENZ Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.